Cytek Biosciences (CTKB) details 2026 shareholder meeting voting outcomes
Rhea-AI Filing Summary
Cytek Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders held on June 10, 2026. Of 129,142,587 common shares outstanding as of April 13, 2026, 111,161,490 were present or represented by proxy, about 86.1% of shares entitled to vote, establishing a strong quorum.
Three director nominees received more votes for than withheld: Vera Imper, Ph.D. (64,769,976 for; 20,723,477 withheld), Glenn P. Muir (79,599,103 for; 5,894,350 withheld) and Ming Yan, Ph.D. (76,741,063 for; 8,752,390 withheld). Two additional matters were also approved, including one that received 84,794,380 votes for and another that received 110,533,253 votes for, each with relatively few votes against.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding: 129,142,587 shares
Shares represented at meeting: 111,161,490 shares
Votes for Glenn P. Muir: 79,599,103 votes
+2 more
5 metrics
Shares outstanding
129,142,587 shares
Common stock outstanding as of April 13, 2026 record date
Shares represented at meeting
111,161,490 shares
Present or by proxy at June 10, 2026 annual meeting (~86.1% of eligible)
Votes for Glenn P. Muir
79,599,103 votes
Director nominee votes for at 2026 annual meeting
Proposal vote
84,794,380 votes for
First non-director proposal with 677,861 against and 21,212 abstentions
Proposal vote
110,533,253 votes for
Second non-director proposal with 479,883 against and 148,354 abstentions
Key Terms
annual meeting of stockholders, record date, broker non-votes, emerging growth company, +1 more
5 terms
annual meeting of stockholders financial
"On June 10, 2026, Cytek Biosciences, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”)."
record date financial
"Of the 129,142,587 shares of the Company’s common stock outstanding as of the close of business on the record date of April 13, 2026..."
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
broker non-votes financial
"Nominee ... Votes For ... Votes Withheld ... Broker Non-Votes ... 25,668,037"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nasdaq Global Select Market financial
"Common Stock, par value $0.001 per share | | CTKB | | Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Cytek Biosciences (CTKB) report from its 2026 annual meeting?
Cytek Biosciences reported detailed voting results from its 2026 annual stockholder meeting, including quorum and vote counts. Three director nominees received more votes for than withheld, and two additional proposals were approved with strong support and relatively few votes cast against.
What were the Cytek Biosciences (CTKB) director nominee vote totals in 2026?
Three director nominees received strong support. Votes for/withheld were: Vera Imper, Ph.D. 64,769,976/20,723,477; Glenn P. Muir 79,599,103/5,894,350; and Ming Yan, Ph.D. 76,741,063/8,752,390, with 25,668,037 broker non-votes on each nominee.
What other proposals did Cytek Biosciences (CTKB) stockholders vote on?
Stockholders voted on two additional proposals. One received 84,794,380 votes for, 677,861 against, and 21,212 abstentions, with 25,668,037 broker non-votes. Another received 110,533,253 votes for, 479,883 against, and 148,354 abstentions, with no broker non-votes reported.
What quorum was achieved at Cytek Biosciences’ 2026 stockholder meeting?
Cytek achieved a high quorum level. Of 129,142,587 common shares outstanding on the April 13, 2026 record date, 111,161,490 shares were present or represented by proxy at the June 10, 2026 meeting, constituting approximately 86.1% of eligible shares.
Who signed the Cytek Biosciences (CTKB) report on the 2026 annual meeting?
The report was signed by Wenbin Jiang, Ph.D., who serves as President and Chief Executive Officer of Cytek Biosciences, Inc. The signature confirms the company’s authorization of the disclosed voting results and related information from the annual meeting.